| Literature DB >> 34716511 |
Wen-Jian Zheng1, Shang-Wen Shi2, Jian Gong3,3.
Abstract
Hypertensive brainstem hemorrhage (HBSH) is of high morbidity and mortality rate. But many clinical studies were written in Chinese and had not been reviewed. A systemic review of Chinese clinical studies for HBSH was performed. A systemic literature search in PubMed, Web of Science, China National Knowledge Infrastructure, and Weipu database and Wanfang database up to March 2020 was performed. Clinical control studies including a surgical evacuation (SE) group and a conservative management (CM) group were included. The clinical outcome and mortality rate were compared. Ten cohort studies were included, involving 944 participants (304 in the SE group and 640 in the CM group). All included patients were comatose, with the average age ranged from 45 to 65 years old. Among five studies using mRS or GOS as outcome score, a total of 16.6% (89/535) of patients achieve self-maintenance with minor disabilities, including 26.8% (34/127) in the SE group and 13.5% (55/408) in the CM group. The overall mortality rate in the SE group was 27.6%, ranged from 9.3 to 60% among different studies. The overall mortality rate in the CM group was 60.6%, ranged from 18.5 to 100.0%. Elder and comatose HBSH patients are not contraindicated for surgery. The review showed that this group of patients obtained a better outcome and lower mortality rate after surgical treatment. The quality of included studies was relatively low, but a high-level clinical study on HBSH is of great difficulty, as both clinicians and patients faced various sociological issues rather than pure medical problems.Entities:
Keywords: Brainstem hemorrhage; Mortality rate; Outcome; Surgery
Mesh:
Year: 2021 PMID: 34716511 PMCID: PMC8555712 DOI: 10.1007/s10143-021-01683-2
Source DB: PubMed Journal: Neurosurg Rev ISSN: 0344-5607 Impact factor: 2.800
Fig. 1The PRISMA flow diagram
Overviews of the ten studies included in the review
| Author | Year | Design | Mean age (years) | History of hypertension | Preoperative angiography | Patient inclusion | Hemorrhage location ( | Mean HV (ml) | Follow-up (months) | MINORS/Cochrane | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MES | PON | MED | ||||||||||
| ZHANG SW | 2019 | NRCCT | 50.5 | 47 (85.5%) | No | GCS 3–8 HV > 5 ml | 9 | 45 | 1 | 8.4 ± 1.5 | 3 | 16 |
| LAN ZG | 2019 | NRCCT | 51.5 | All | Yes | GCS 3–8 | 54 | 208 | 24 | 8.7 ± 0.5 | 6 | 20 |
| LV CL | 2019 | NRCCT | NM | All | No | GCS 3–7 | 37 | 71 | 0 | 11.3 | 3 | 16 |
| ZHANG YQ | 2017 | NRCCT | 47.1 ± 8.4 | All | Yes | GCS 3–8 HV ≥ 5 ml | 43 | 14 | 8 | 8.1 ± 1.4 | 3 | 17 |
| HUANG KY | 2016 | NRCCT | 48.5 ± 5.1 | All | No | Comatose HV 5–10 ml | NM | NM | 12 | 15 | ||
| ZONG L | 2016 | NRCCT | 58.9 ± 6.3 | All 8 surgery patients | No | GCS 3–5 HV 5–20 ml | 40 | 0 | NM | 3 | 13 | |
| CHEN QM | 2015 | NRCCT | 52.5 | All | No | GCS 3–8 | NM | NM | 3 | 15 | ||
| KU HB | 2014 | RCT | 65.2 | 115 (84.6%) | No | GCS 3–10 HV 5–20 ml | 0 | 136 | 0 | 11.8 | 1 | High risk |
| WANG J | 2014 | NRCCT | 54.5 | All | No | GCS 3–8 | 21 | 89 | 18 | 8.0 | 3 | 16 |
| HUANG JL | 2010 | RCT | 57 | All | No | GCS 3–8 HV ≥ 7 ml | 0 | 21 | 0 | 11.5 | 6 | High risk |
GOS Glasgow Outcome Scale, GCS Glasgow Coma Scale, HV hematoma volume, MED medullary, MES mesencephalic, NRCCT non-randomized concurrent controlled trials, NM not mention, mRS modified Rankin scale, PON pontine, RCT randomized controlled trials
Patient outcome and complications compared in ten studies
| Author | Year | Treatment | EVD in CM group | Outcome assessment | Good outcome | Mortality rate | Follow-up (months) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Surgery | Control | Surgery | Control | ||||||||
| ZHANG SW | 2019 | Stereotactic aspiration | Yes | mRS < 3 | 7/19 36.8% | 6/36 16.7% | 0.094 | 4/19 21.1% | 16/36 44.4% | 0.086 | 3 |
| LAN ZG | 2019 | Microscope | No | mRS < 3 | 11/46 23.9% | 45/240 18.8% | 0.419 | 14/46 30.4% | 169/240 70.4% | 6 | |
| LV CL | 2019 | Stereotactic aspiration | No | NIHSS ↓45% | 25/43 58.1% | 20/65 30.8% | 4/43 9.3% | 12/65 18.5% | 0.190 | 3 | |
| ZHANG YQ | 2017 | Aspiration | No | Barthel index > 40 | 8/32 25.0% | 1/33 3.0% | 18/32 56.3% | 27/33 81.8% | 3 | ||
| HUANG KY | 2016 | Microscope | YES | NIHSS ↓45% | 17/30 56.7% | 12/30 40.0% | 0.196 | 4/30 13.3% | 11/30 36.7% | 12 | |
| ZONG L | 2016 | Microscope | No | Barthel index > 60 | 4/8 50.0% | 11/32 34.4% | 0.414 | 2/8 25.0% | 13/32 40.6% | 0.414 | 3 |
| CHEN QM | 2015 | Microscope | No | GOS > 3 | 1/15 6.7% | 0/30 0% | 0.333* | 9/15 60.0% | 29/30 96.7% | 3 | |
| KU HB | 2014 | Stereotactic aspiration | Yes | NIHSS ↓45% | 25/64 39.0% | 9/72 12.5% | 13/64 30.3% | 42/72 58.3% | 1 | ||
| WANG J | 2014 | Microscope | No | GOS > 3 | 10/37 27.2% | 4/91 4.4% | 14/37 37.8% | 58/91 63.7% | 3 | ||
| HUANG JL | 2010 | Stereotactic aspiration | No | GOS > 3 | 5/10 50.0% | 0/11 0% | 2/10 20.0% | 11/11 100.0% | 6 | ||
CM conservative treatment, EVD external ventricular drainage, GOS Glasgow Outcome Scale, mRS modified Rankin scale, NIHSS National Institute of Health stroke scale, *Fisher’s exact test, bold type indicates significant difference (P < 0.05)
Major complications reported by four studies
| Author | Year | Pneumonia | Stress ulcer | Renal failure | Others | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Surgery | Control | Surgery | Control | Surgery | Control | Surgery | Control | |||||
| LAN ZG | 2019 | 14/46 | 89/240 | 0.390 | 12/46 | 57/240 | 0.734 | NM | NM | NM | NM | |
| LV CL | 2019 | 1/43 | 13/65 | 5/43 | 5/65 | 0.754 | 2/43 | 6/65 | 0.607 | NM | NM | |
| WANG J | 2014 | 6/128 | 3/128 | 12/128 | Respiratory failure 47/128 | |||||||
| HUANG JL | 2010 | 1/10 | 2/11 | 1.000 | 1/10 | 2/11 | 1.000 | 1/10 | 3/11 | 0.652 | Hydrocephalus 1/10 Hepatic failure 1/10 MODS 1/10 | Hydrocephalus 10/11 Hepatic failure 1/11 MODS 1/11 |
MODS multiple organ dysfunction syndrome, NM not mention, bold type indicates significant difference (P < 0.05)